Pulse.

a daily field guide to health research that matters

◆ Console

‹ Mon · 26 Oct 2026
Standard addition

Adjuvant olaparib for patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer: real-world data from a French early access program.

Olaparib extends survival in BRCA-positive early breast cancer patients after surgery, offering hope for those carrying these gene mutations.

In the OlympiA trial, adjuvant olaparib improved survival in patients with germline BRCA1 / BRCA2 mutations (gBRCAm) and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (eBC). The record provides preliminary or context-setting evidence for this research question.

What the study was

Study design
Observational or experimental study
Population
In the OlympiA trial, adjuvant olaparib improved survival in patients with germline BRCA1 / BRCA2 mutations (gBRCAm) and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (eBC).
Sample size
308
Category
Treatment Innovation
Maturity
Exploratory
Journal
ESMO Real World Data Digit Oncol

Why it surfaced

Observational or experimental study with a PubMed abstract reviewed; the 7/10 score reflects conservative novelty, relevance, design-quality, and population/unmet-need assessment.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.